RADVAX RCC is a phase 2 trial evaluating the efficacy and safety of combined dual checkpoint inhibition – with nivolumab plus ipilimumab – and stereotactic body radiotherapy (SBRT) in the metastatic renal cell carcinoma (mRCC) setting.
The first results were presented at ASCO GU 2020 and suggest that combining checkpoint inhibitors with SBRT is feasible in patients with mRCC.